CA 15-3 serum levels in patients with ductal breast carcinoma: Relationship with clinicopathological parameters and tumor markers

International Journal of Biological Markers

Volumn 27, Issue 1, 2012, Pages 47-52

  González Sistal, Angel ^a   Arias, JoséIgnacio ^b   Ruibal, Álvaro ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Hospital Monte del Naranco   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Breast carcinoma; CA 15 3; Cathepsin D; Epidermal growth factor receptor (EGFR); S phase

Indexed keywords

ANDROGEN RECEPTOR; CA 15-3 ANTIGEN; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN PS2;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER SIZE; CELL MEMBRANE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; LYMPH NODE; MAJOR CLINICAL STUDY; PLOIDY; POSTMENOPAUSE; PREOPERATIVE EVALUATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOASSAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATHEPSIN D; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MUCIN-1; PRESENILIN-2; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863917824     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8591     Document Type: Article

References (21)

1. Van der Vegt B, de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.Histopathology 2007; 51: 322-335.
2. Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 2008; 68: 6136-6144.
3. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008; 1: 3116-3125.
4. Baskic D, Ristic P, Matic S, Bankovic D, Popovic S, Arsenijevic N: Clinical evaluation of the simultaneous determination of CA15.3, CA125 and SHER2 in breast cancer. Biomarkers 2007; 12: 657-667.
5. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. Clin Chem 2008; 54: 111-179.
6. Harris L, Fritsche H, Mennel R, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5278-5312.
7. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value?. Clin Chem 2006; 52: 345-351.
8. Duffy MJ, Duggan C, Keane R, et al. High preoperative CA15.3 concentrations predict adverse outcome in node negative and node positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50: 559-563.
9. Park BW, Oh JW, Kim JH, et al. Preoperative CA15.3 and CEA serum levels as predictor for breast cancer. Ann Oncol 2008; 19: 675-681.
10. Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. Totowa, NJ: Humana Press, 2006.
11. Diamandis EP, Schwartz MK. Tumor markers: Physiology, pathobiology, technology, and clinical applications. Washington, DC: AACC Press, 2002.
12. Elliott RL, Head JF. Breast cancer tumor markers: worthless or beneficial. Cancer Detec Prev 2008; 32: 188-189.
13. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, Fukutomi T. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen CA15.3 (CA15.3) in breast cancer. Int J Clin Oncol 2008; 13: 447-451.
14. Prasad AR, Divine G, Zarbo JR. Two-color, cytokeratin-labeled dna flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up. Arch Pathol Lab Med. 2001; 125: 364-374.
15. Berchem G, Glondu M, Gleizes M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002; 21: 5951-5955.
16. González-Sistal A, Arias JI, Baltasar Sánchez A, Ruibal A. Relationship between cathepsin D and CA15-3 antigen for breast cancer. Clin Chem 2010, 56: A187.
17. Benes P, Vetvicka V, Fusek M. Cathepsin D-Many functions of one aspartic protease. Crit Rev Oncol Hematol 2008; 68: 12-28.
18. Singh AP, Senapati S, Ponnusamy M, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008; 9: 1076-1085.
19. Steffensen KD, Waldstrøm M, Andersen RF, et al. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol 2008; 33: 195-204.
20. Croce MV, Isla-Larrain MT, Demichelis SO, Gori JR, Price MR, Segal-Eiras A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res Treat 2003; 81: 195-207.
21. Asgeirsson KS, Agrawal A, Allen C, et al. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 2007; 9: R75.